Search

everythinglearnresearchcommunity

for

Search:↓

Understanding and managing side effects of hedgehog pathway inhibitors can improve treatment for advanced basal cell carcinoma.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Combining SVF and PRP speeds up wound healing.

A new cream, DHMEQ, reduces allergic skin inflammation effectively.

Drug repurposing speeds up drug development, saves money, and has led to about a third of new drug approvals.

There is no gold standard treatment for hidradenitis suppurativa due to insufficient evidence.

Natural volatiles and essential oils have health benefits and can enhance the effects of some medicines, but more research is needed to understand how they work and their possible side effects.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.

Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Tempol is safe and may prevent hair loss from brain radiotherapy.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Topical bexarotene 1% gel might help regrow hair in alopecia areata and is generally safe.

The drug combination was safe and showed promise in treating advanced tumors.

The goal is to create a tool for patients to report their experiences with various hair and scalp disorders.

IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

Drug metabolism affects how long a drug works, its interactions, activation, and toxicity, and is influenced by genetics, diet, illness, and other drugs.

New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Compounds from certain trees used by First Nations people show potential for treating skin conditions and promoting hair growth, but more research is needed to confirm their safety and effectiveness.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.